Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems

This article elaborates on the pathophysiology of IPF, its risk factors, and different advanced drug delivery systems for treating IPF. Although extensive preclinical data is available for these delivery systems, the clinical performance and scale-up studies would decide their commercial translation.PMID:38589751 | DOI:10.1208/s12249-024-02793-y
Source: AAPS PharmSciTech - Category: Drugs & Pharmacology Authors: Source Type: research